Send to

Choose Destination
Oncoimmunology. 2013 Dec 1;2(12):e27059. Epub 2013 Nov 6.

Dendritic cell-based immunotherapy in ovarian cancer.

Author information

Department of Gynecologic Oncology; Leuven Cancer Institute, KU Leuven, Belgium.
Department of Microbiology and Immunology; KU Leuven, Belgium.


Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise. Here, we present our view on an optimal dendritic cell-based immunotherapeutic strategy against ovarian cancer.


DC; DC immunotherapy; WT1; dendritic cell; ovarian cancer

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center